Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow SNMMI on Twitter
  • Visit SNMMI on Facebook
OtherClinical Investigations (Human)

QUANTIFICATION OF METASTATIC PROSTATE CANCER WHOLE-BODY TUMOR BURDEN WITH FDG PET PARAMETERS AND ASSOCIATIONS WITH OVERALL SURVIVAL AFTER FIRST LINE ABIRATERONE OR ENZALUTAMIDE: A SINGLE- CENTER RETROSPECTIVE COHORT STUDY

Andreas G. Wibmer, Michael J. Morris, Mithat Gonen, Junting Zheng, Hedvig Hricak, Steven M. Larson, Howard I. Scher and Hebert Alberto Vargas
Journal of Nuclear Medicine January 2021, jnumed.120.256602; DOI: https://doi.org/10.2967/jnumed.120.256602
Andreas G. Wibmer
Memorial Sloan Kettering Cancer Center, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Andreas G. Wibmer
Michael J. Morris
Memorial Sloan Kettering Cancer Center, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mithat Gonen
Memorial Sloan Kettering Cancer Center, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Junting Zheng
Memorial Sloan Kettering Cancer Center, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hedvig Hricak
Memorial Sloan Kettering Cancer Center, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven M. Larson
Memorial Sloan Kettering Cancer Center, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Howard I. Scher
Memorial Sloan Kettering Cancer Center, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hebert Alberto Vargas
Memorial Sloan Kettering Cancer Center, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Article Information

jnumed.120.256602
DOI 
https://doi.org/10.2967/jnumed.120.256602
PubMed 
33419944

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Published online January 8, 2021.

Copyright & Usage 
Copyright © 2021 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

Author Information

  1. Andreas G. Wibmer,
  2. Michael J. Morris,
  3. Mithat Gonen,
  4. Junting Zheng,
  5. Hedvig Hricak,
  6. Steven M. Larson,
  7. Howard I. Scher and
  8. Hebert Alberto Vargas
  1. Memorial Sloan Kettering Cancer Center, United States
  1. For correspondence or reprints contact: Andreas G. Wibmer, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, United States. E-mail: wibmera@mskcc.org

Article usage

Article usage: to

AbstractFullPdf
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 62 (2)
Journal of Nuclear Medicine
Vol. 62, Issue 2
February 1, 2021
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
QUANTIFICATION OF METASTATIC PROSTATE CANCER WHOLE-BODY TUMOR BURDEN WITH FDG PET PARAMETERS AND ASSOCIATIONS WITH OVERALL SURVIVAL AFTER FIRST LINE ABIRATERONE OR ENZALUTAMIDE: A SINGLE- CENTER RETROSPECTIVE COHORT STUDY
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
QUANTIFICATION OF METASTATIC PROSTATE CANCER WHOLE-BODY TUMOR BURDEN WITH FDG PET PARAMETERS AND ASSOCIATIONS WITH OVERALL SURVIVAL AFTER FIRST LINE ABIRATERONE OR ENZALUTAMIDE: A SINGLE- CENTER RETROSPECTIVE COHORT STUDY
Andreas G. Wibmer, Michael J. Morris, Mithat Gonen, Junting Zheng, Hedvig Hricak, Steven M. Larson, Howard I. Scher, Hebert Alberto Vargas
Journal of Nuclear Medicine Jan 2021, jnumed.120.256602; DOI: 10.2967/jnumed.120.256602

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
QUANTIFICATION OF METASTATIC PROSTATE CANCER WHOLE-BODY TUMOR BURDEN WITH FDG PET PARAMETERS AND ASSOCIATIONS WITH OVERALL SURVIVAL AFTER FIRST LINE ABIRATERONE OR ENZALUTAMIDE: A SINGLE- CENTER RETROSPECTIVE COHORT STUDY
Andreas G. Wibmer, Michael J. Morris, Mithat Gonen, Junting Zheng, Hedvig Hricak, Steven M. Larson, Howard I. Scher, Hebert Alberto Vargas
Journal of Nuclear Medicine Jan 2021, jnumed.120.256602; DOI: 10.2967/jnumed.120.256602
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Clinical Investigations (Human)

  • Assessment and comparison of fluorocholine PET and sestamibi scans in identifying parathyroid adenomas: a meta-analysis
  • Simulation of low dose protocols for myocardial perfusion 82Rubidium imaging
Show more Clinical Investigations (Human)

Clinical (Oncology: GU)

  • Detection of Early Progression with 18F-DCFPyL PET/CT in Men with Metastatic Castration-Resistant Prostate Cancer Receiving Bipolar Androgen Therapy
  • A novel time-activity information sharing approach using nonlinear mixed models for patient-specific dosimetry with reduced imaging time points: application in SPECT/CT imaging post-177Lu-DOTATATE
Show more Clinical (Oncology: GU)

Similar Articles

Keywords

  • Genitourinary
  • Molecular imaging
  • Oncology: GU
  • PET/CT
  • 18F-fluoro-desoxy-glucose positron-emission tomography computed tomography
  • abiraterone; enzalutamide
  • metastatic prostate cancer
  • overall survival
  • whole-body tumor burden
SNMMI

© 2021 Journal of Nuclear Medicine

Powered by HighWire